Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gossamer Bio (GOSS) Change in Receivables (2024 - 2025)

Gossamer Bio's Change in Receivables history spans 2 years, with the latest figure at $3.0 million for Q4 2025.

  • For Q4 2025, Change in Receivables rose 338.72% year-over-year to $3.0 million; the TTM value through Dec 2025 reached $6.9 million, up 29.06%, while the annual FY2025 figure was $6.9 million, 29.06% up from the prior year.
  • Change in Receivables reached $3.0 million in Q4 2025 per GOSS's latest filing, up from $1.7 million in the prior quarter.
  • In the past five years, Change in Receivables ranged from a high of $3.6 million in Q2 2024 to a low of -$1.2 million in Q4 2024.